CHICAGO — The federal government’s new advice to doctors for helping smokers quit recommends the drug Chantix, which has recently been linked with depression and suicidal behavior.
The new guidelines mention the psychiatric risks but also say the popular Pfizer Inc. drug is the most effective at helping people get off cigarettes. The guidelines mention other options, too, and highly recommend combining counseling and medication.
Consumer advocates cautioned that the safety picture on Chantix is incomplete because it’s a relatively new drug, on the market just since 2006.
“It is somewhat better than other therapies; on the other hand, it appears to have more risk,” said Dr. Sidney Wolfe of the watchdog group Public Citizen.
Another issue with the quit-smoking guidelines, released this week by the U.S. Public Health Service, is the lead author’s past connections with Pfizer.
Dr. Michael Fiore, an expert on smoking and health issues, was a consultant to the maker of Chantix. But he said he cut those ties in 2005.
Fiore’s views are shaped by his past ties to the drug industry, and those ties still pose a conflict, at least one consumer advocate said.
John Polito, a smoking-cessation educator who runs the site that advocates quitting “cold turkey,” called the revised guidelines “a sales pitch” for the drug industry.
The task force overlooked research showing that quitting cold turkey works, Polito said, and studies showing Chantix is superior don’t reflect how it’s used “in the real world.”
“People are quitting smoking to save their lives,” Polito said.
If Chantix’s risks outweigh its benefits, “then it’s insane for people to risk their lives” by using it, he said.
